Display options
Cite
Lancon C, Dassa D, Fernandez J, et al. Are cardiovascular risk factors associated with verbal learning and memory impairment in patients with schizophrenia? A cross-sectional study. Cardiovasc Psychiatry Neurol. 2012;2012:204043doi: 10.1155/2012/204043.
Lancon, C., Dassa, D., Fernandez, J., Richieri, R., Padovani, R., & Boyer, L. (2012). Are cardiovascular risk factors associated with verbal learning and memory impairment in patients with schizophrenia? A cross-sectional study. Cardiovascular psychiatry and neurology, 2012204043. https://doi.org/10.1155/2012/204043
Lancon, Christophe, et al. "Are cardiovascular risk factors associated with verbal learning and memory impairment in patients with schizophrenia? A cross-sectional study." Cardiovascular psychiatry and neurology vol. 2012 (2012): 204043. doi: https://doi.org/10.1155/2012/204043
Lancon C, Dassa D, Fernandez J, Richieri R, Padovani R, Boyer L. Are cardiovascular risk factors associated with verbal learning and memory impairment in patients with schizophrenia? A cross-sectional study. Cardiovasc Psychiatry Neurol. 2012;2012:204043. doi: 10.1155/2012/204043. Epub 2012 Nov 19. PMID: 23227310; PMCID: PMC3512211.
Copy Download .nbib Format: NLM
Share it on

Cardiovasc Psychiatry Neurol. 2012;2012:204043. doi: 10.1155/2012/204043. Epub 2012 Nov 19.

Are cardiovascular risk factors associated with verbal learning and memory impairment in patients with schizophrenia? A cross-sectional study.

Cardiovascular psychiatry and neurology

Christophe Lancon, Daniel Dassa, Jessica Fernandez, Raphaelle Richieri, Romain Padovani, Laurent Boyer

Affiliations

  1. EA 3279-Public Health, Chronic Disease, and Quality of Life Research Unit, Aix-Marseille University, 13005 Marseille, France ; Department of Psychiatry, Sainte-Marguerite University Hospital, 13009 Marseille, France ; Department of Addiction, Sainte-Marguerite University Hospital, 13009 Marseille, France.

PMID: 23227310 PMCID: PMC3512211 DOI: 10.1155/2012/204043

Abstract

Objective. The aim of this study is to assess the relationships of cardiovascular risk factors with verbal learning and memory in patients with schizophrenia. Methods and Design. cross-sectional study. Inclusion Criteria. Diagnosis of schizophrenia according to the DSM-IV-TR criteria. Data Collection. Sociodemographic information, clinical characteristics, anthropometric measurements, blood tests, and episodic memory using the California Verbal Learning Test (CVLT). Analysis. A multivariate analysis using multiple linear regressions was performed to determine variables that are potentially associated with verbal learning and memory. Results. One hundred and sixty-eight outpatients participated in our study. An association was found between the metabolic syndrome (MetS) and memory impairment on measures of verbal learning, and short- and long-term memory. Among the different components of MeTS, hypertriglycerides, abdominal obesity, and low HDL cholesterol were the only factors associated with memory impairment. Alcohol dependence or abuse was associated with a higher rate of forgetting. Conclusion. Our findings suggest that MetS and alcohol use may be linked with memory impairment in schizophrenia. These findings provide important insights into the interdependencies of cardiovascular risk factors and cognitive disorders and support novel strategies for treating and preventing cognitive disorders in patients with schizophrenia.

References

  1. Schizophr Bull. 1999;25(2):233-55 - PubMed
  2. Int J Obes Relat Metab Disord. 2004 Jan;28(1):34-8 - PubMed
  3. Neurology. 2005 Jan 25;64(2):277-81 - PubMed
  4. Psychiatry Res. 2011 Dec 30;190(2-3):187-92 - PubMed
  5. Psychiatr Serv. 2001 Apr;52(4):469-76 - PubMed
  6. JAMA. 2004 Nov 10;292(18):2237-42 - PubMed
  7. J Neurobiol. 2002 Dec;53(4):641-55 - PubMed
  8. Arch Neurol. 2007 Dec;64(12):1734-40 - PubMed
  9. Arch Gen Psychiatry. 2006 Jun;63(6):630-8 - PubMed
  10. Circulation. 2005 Oct 25;112(17):2735-52 - PubMed
  11. Acta Psychiatr Scand. 2009 Aug;120(2):85-96 - PubMed
  12. Cell Mol Neurobiol. 2007 Aug;27(5):609-39 - PubMed
  13. Peptides. 2006 Nov;27(11):2738-49 - PubMed
  14. Neurobiol Aging. 2009 Sep;30(9):1483-9 - PubMed
  15. Br J Psychiatry. 1986 Oct;149:439-48 - PubMed
  16. Diabetes Care. 2007 Oct;30(10):2655-60 - PubMed
  17. Biochim Biophys Acta. 2009 May;1792(5):470-81 - PubMed
  18. Schizophr Res. 2004 Dec 15;72(1):29-39 - PubMed
  19. Schizophr Bull. 2005 Jan;31(1):175-82 - PubMed
  20. J Clin Psychopharmacol. 2004 Oct;24(5 Suppl 1):S7-14 - PubMed
  21. Schizophr Res. 2009 Oct;114(1-3):98-104 - PubMed
  22. J Clin Med Res. 2012 Jun;4(3):206-8 - PubMed
  23. Psychiatry Res. 2012 Jul 30;198(2):212-5 - PubMed
  24. Eur J Neurol. 2009 Sep;16(9):1022-7 - PubMed
  25. Br J Addict. 1991 Sep;86(9):1119-27 - PubMed
  26. Am J Psychiatry. 2010 Oct;167(10):1155-7 - PubMed
  27. Neuropharmacology. 2012 Mar;62(3):1564-73 - PubMed
  28. Arch Gen Psychiatry. 2004 Nov;61(11):1107-15 - PubMed
  29. Am J Orthopsychiatry. 1998 Apr;68(2):176-8 - PubMed
  30. Am J Psychiatry. 2010 Oct;167(10):1232-9 - PubMed
  31. Clin Cardiol. 2002 May;25(5):205-12 - PubMed
  32. Biol Psychiatry. 2012 Mar 15;71(6):545-51 - PubMed
  33. Schizophr Res. 2011 Sep;131(1-3):174-83 - PubMed
  34. Neuroscience. 2002;113(3):607-15 - PubMed
  35. Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17(5):460-6 - PubMed
  36. Schizophr Bull. 2013 Mar;39(2):306-18 - PubMed
  37. Schizophr Res. 2005 Dec 1;80(1):9-18 - PubMed

Publication Types